Greenwich LifeSciences, Inc.
GLSI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001799788
In the last 90 days, Greenwich LifeSciences, Inc. insiders filed 3 open-market purchases and 0 sales; 57 institutions reported holding it in 13F filings for Q2 2026, worth $39.6M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Greenwich LifeSciences, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 34 | 1 | 34 | +1 |
| Shares | 931.2K | 667 | 1.03M | +101.7K (+10.9%) |
| Value | $18.3M | $13.0K | $8.74M | −$9.53M (−52.2%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Greenwich LifeSciences, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 105,159 | $891.0K | 0.00% |
| Millennium Management LLC | 90,292 | $765.0K | 0.00% |
| Occudo Quantitative Strategies LP | 23,440 | $199.0K | 0.02% |
| Two Sigma Investments, LP | 21,431 | $182.0K | 0.00% |
| Ergoteles LLC | 20,000 | $169.0K | 0.01% |
| Schonfeld Strategic Advisors LLC | 17,800 | $151.0K | 0.00% |
| Citadel Advisors LLC | 17,657 | $150.0K | 0.00% |
| D. E. Shaw & Co., Inc. | 17,631 | $149.0K | 0.00% |
| Cubist Systematic Strategies, LLC | 15,332 | $130.0K | 0.00% |
| Goldman Sachs Group Inc | 12,322 | $104.0K | 0.00% |
| Walleye Capital LLC | 10,656 | $90.0K | 0.00% |
| Founders Capital Management | 1,000 | $8.00K | 0.01% |
| Credit Suisse AG | 2 | $0 | 0.00% |
| Captrust Financial Advisors | 19 | $0 | 0.00% |
Sold out (13)
Institutions that held Greenwich LifeSciences, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Northern Trust Corp | 35,060 | $688.0K |
| Nuveen Asset Management, LLC | 9,575 | $206.0K |
| Charles Schwab Investment Management Inc | 10,191 | $200.0K |
| Bank of New York Mellon Corp | 10,114 | $198.0K |
| Nisa Investment Advisors, LLC | 7,200 | $141.0K |
| Deutsche Bank AG | 2,192 | $43.0K |
| American International Group, Inc. | 2,030 | $40.0K |
| California State Teachers Retirement System | 1,781 | $35.0K |
| STRS Ohio | 900 | $17.0K |
| Barclays PLC | 665 | $13.0K |
| Amalgamated Bank | 667 | $13.0K |
| Legal & General Group Plc | 427 | $8.00K |
| Ameritas Investment Partners, Inc. | 316 | $6.00K |
Not filed for Q2 2022 yet (1)
Institutions that held Greenwich LifeSciences, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Amalgamated Financial Corp. | 667 | $13.0K |